---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-012786"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:09:51.616547+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Anebulo reports Q3 FY2022 net loss $1.9M; Phase 2 trial fully enrolled

## Summary
- Net loss of $1.9M ($0.08/share) for Q3 FY2022 vs $0.6M ($0.68/share) year ago.
- Operating expenses rose to $1.9M from $0.6M in prior year period.
- Cash and cash equivalents totaled $16.5M as of March 31, 2022.
- Completed enrollment of 60 subjects in Part A of Phase 2 trial for ANEB-001; top-line data expected by June 30, 2022.
- Company scheduled to present at four investor conferences and a cannabinoid symposium in May-June 2022.

## SEC filing metadata
- accession: 0001493152-22-012786
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315222012786/0001493152-22-012786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315222012786/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-012786
- JSON: https://secwatch.observer/filing/0001493152-22-012786.json
- Plain text: https://secwatch.observer/filing/0001493152-22-012786.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.